Illumina Appoints Eli Lilly's Chief Scientific Officer to its Board of Directors

Illumina announced it has appointed Dr. Daniel M. Skovronsky to its Board of Directors, effective June 16, 2026. In connection with the appointment, the company's Board was expanded from nine to ten members. Dr. Skovronsky brings extensive experience in drug discovery, clinical development, and translational medicine.

Key Details

• New Director: Daniel M. Skovronsky, M.D., Ph.D., currently Chief Scientific and Product Officer of Eli Lilly and Company.
• Effective Date: The appointment was effective June 16, 2026.
• Terms: Dr. Skovronsky qualifies as an independent director and will stand for election at Illumina's 2027 annual meeting of stockholders.